Last reviewed · How we verify
REPEVAX™ (Concomitant)
REPEVAX is a booster vaccine that provides protection against diphtheria, tetanus, pertussis, and poliomyelitis by stimulating immune memory responses.
REPEVAX is a booster vaccine that provides protection against diphtheria, tetanus, pertussis, and poliomyelitis by stimulating immune memory responses. Used for Booster vaccination against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults.
At a glance
| Generic name | REPEVAX™ (Concomitant) |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Inactivated combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
REPEVAX contains inactivated toxoids and antigens from Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, and poliovirus types 1, 2, and 3. When administered as a booster dose, it reactivates and reinforces the adaptive immune response (both humoral and cellular) against these pathogens, maintaining protective antibody levels and cellular immunity in previously vaccinated individuals.
Approved indications
- Booster vaccination against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults
Common side effects
- Injection site reactions (pain, redness, swelling)
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- Pertussis and Meningitis C Concomitant Vaccination in Adolescents (PHASE4)
- A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) (PHASE3)
- Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REPEVAX™ (Concomitant) CI brief — competitive landscape report
- REPEVAX™ (Concomitant) updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI